Upstream Bio Expands IPO to $255 Million, Set to Join Nasdaq Alongside CAMP4

IPO Expansion:
Upstream Bio has increased its initial public offering (IPO) to $255 million as it prepares to list on the Nasdaq stock exchange.

Nasdaq Listing:
The company will join the Nasdaq alongside CAMP4, marking a significant milestone in the biotech sector.

Focus Area:
Upstream Bio specializes in developing novel therapies for inflammatory and allergic diseases.

Investment Background:
Access Industries participated in Upstream Bio's $200 million Series A financing in June 2022, demonstrating its commitment to biotechnology investments.

Market Context:
The biotech sector has seen a steady trickle of IPOs, with Upstream Bio and CAMP4 being the latest additions.